Stocks Health care TNYA
NASDAQ · Health careTenaya Therapeutics, Inc. (TNYA)
It posted a net loss of $103.1M. In fiscal 2025 capital spending exceeded operating cash flow by $68.9M. At June 30, 2026 it held $78.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 5, 2026.
What Tenaya Therapeutics, Inc. does
Tenaya Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker TNYA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$90.6M | -$0.59 | -$68.9M |
| 2024 | n/a | -$111.1M | -$1.31 | -$91.5M |
| 2023 | n/a | -$124.1M | -$1.68 | -$103.3M |
| 2022 | n/a | -$123.7M | -$2.76 | -$125.1M |
| 2021 | n/a | -$72.7M | -$4.10 | -$85.9M |
| 2021 | n/a | -$38.4M | -$39.50 | -$45.2M |
Latest SEC filings
What Tenaya Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 24, 2026Passive stake (5% or more) SCHEDULE 13G
- August 5, 2026
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026
- August 5, 2026
- July 2, 2026
- June 29, 2026
- May 29, 2026
- May 6, 2026Quarterly report 10-Q · period to March 31, 2026
- May 6, 2026
- April 16, 2026
Insider trades
What the people running Tenaya Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 2 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 10, 2026 | Tingley WhittemoreChief Medical Officer | Received as pay | 49,000 | - |
| September 10, 2026 | Ali FarazChief Executive Officer, Director | Received as pay | 122,000 | - |
Questions about TNYA
What does Tenaya Therapeutics, Inc. do?
Tenaya Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker TNYA.
Is Tenaya Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $103.1M.
When did Tenaya Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 5, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 11, 2026.
Similar companies
Compare TNYA with
Follow TNYA
Get an email when Tenaya Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow TNYA: get an email when it filesWhere the numbers come from
Financial figures are the values Tenaya Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.